Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent…
Microsoft’s AI-Fueled Record Quarter Reframes Long-Term Investment Trade Offs
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Genesis Energy signs exclusivity deal with Yinson for New Zealand wind projects
Genesis is also exploring offshore wind opportunities. Genesis and Taranaki Offshore Partnership, the joint venture between the New…